Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol versus medroxyprogesterone for menopausal vasomotor symptoms
IRCT20210412050945N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in vasomotor symptoms and hot flash comparing Megestrol with Medroxyprogesterone (2 arms). Primary endpoint: Intensity of hot flushing and sweating. Started May 2021; status: completed.
02
Drugs
megestrolmedroxyprogesterone acetate
03
Conditions
vasomotor symptomshot flash
Beyond the preview
Go deeper on IRCT20210412050945N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210412050945N1.